Tempus AI's dual-engine model drives $1.27B revenues, with Diagnostics dominating and Data monetization accelerating growth ...

AI is rewriting drug discovery. Recursion Pharmaceuticals and Tempus AI might be the platforms that turn early investors into millionaires.

It's been a busy summer for Tempus AI (NASDAQ: TEM). Founded in August 2015, the company is celebrating its 10-year anniversary this month. Tempus AI also recently celebrated its one-year anniversary ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61.40, ...

Reported preliminary, unaudited Data and application revenue of ~$316 million for the full year 2025, representing ~31% year-over-year growth, with Insights (data licensing) growing 38% 2025 Net ...

Tempus AI Inc (NASDAQ:TEM) shares are trading lower by 1.7% to $53.15 Tuesday afternoon. The company will report its first-quarter earnings after Tuesday's market close, with analysts expecting a loss ...

Tempus AI (NASDAQ: TEM) has been publicly traded for only 16 months, and it has been nothing short of a market standout over that time. Compared to its IPO price of $37, Tempus shares were up by a ...

Editor's Note: This story was initially published May 21. It was updated June 7 with IPO pricing information. Three years after talks of an IPO surfaced, health tech company Tempus AI lit the fuse and ...

Tempus enters earnings with strong tailwinds but elevated scrutiny. The stock has surged over 80% in the past six months, and analysts have maintained tight but bullish targets — averaging $61.40, ...

Tempus AI and Merck announced an expanded multi year collaboration focused on AI driven precision medicine and drug discovery in oncology and other therapeutic areas. The partnership aims to combine ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® ...

Tempus AI is using the power of artificial intelligence to improve patient care. After holding its IPO in June 2024, Tempus AI stock has experienced some significant price swings. Despite its rise ...